Discover the Science of Health
A recent study published in the journal Epilepsia indicates that there is a bidirectional relationship between schizophrenia and epilepsy [1]. This means that people with schizophrenia are at a higher risk of developing epilepsy, and those with epilepsy face a higher risk of developing schizophrenia. The fact that each disorder acts as a risk factor for the other indicates that the two may share some underlying causative factors, be they genetic, environmental, or neurological in origin.
In the drug discovery pipeline, Phase I trials are first used to evaluate if a new drug is safe, then Phase II trials are done to assess the drug’s efficacy, and finally Phase III trials are performed to monitor side effects and compare the drug to similar compounds already on the market. Each consecutive phase includes more people to refine the results obtained in the previous phase. A recent analysis by the Centre for Medicines Research in the UK has concluded that since 2008, the failure rate for drugs in Phase II and III clinical trials has been rising [1-2]. Phase II success rates are currently at 18%, lower than at any other phase of drug development.
Antibiotic resistance is an ever-growing clinical problem. Four years ago, a study found that antibiotics are overprescribed for sinus infections. Compounding the issue is the fact that as bacteria are learning to tolerate and even circumvent existing classes of antibiotics, not enough work is being done to discover new ones. Combinations or cocktails of antibiotics are often used to broaden the antimicrobial spectrum of each and to achieve synergistic effects; this approach has successfully been applied to combat tuberculosis, leprosy, malaria, and famously, HIV. Yet the discovery of effective combinations has usually been almost fortuitous, most often resulting from trial and error rather than a systematic analysis.
In the current study, researchers systematically examined combinations of 1,057 compounds previously approved as drugs to find those that exhibited synergy with the antibiotic minocycline. Their work is reported in the April 24, 2011 issue of the journal Nature Chemical Biology [1]. The compounds were chosen because they have already been approved as drugs, they are known to have activity in vivo and are known to be relatively safe. Many approved drugs are known to have utility for clinical indications other than those for which they initially received approval. Moreover, using pre-approved compounds also reduces the time and cost associated with developing new compounds for therapeutic use.
It is difficult to find a school, camp or other facility catering to children these days that is not nut free. The prevalence of peanut allergies in preschool and school age children in the UK, the US and Canada is between 1.2 – 1.6%, which is about twice the rate at which it occurs in adults in these countries. Nut allergies, especially peanut allergies, are scary. And although they have been on the rise, no one really knows why. Researchers in Scotland recently reported in The Journal of Allergy and Clinical Immunology that mutations in the gene for filaggrin, a protein found in skin, are a “significant risk factor for peanut allergy” [1].
Memories are fragile; initially forming and then retrieving them are both dependent on new protein synthesis in the brain, and both processes are vulnerable to disruption. A number of agents are known that can impair memory and these can certainly be useful — for example, in treating post-traumatic stress disorder (ptsd). Enhancing memory, however, has proven more difficult. Yet as noted in The New York Times last week [1], two different research groups have recently reported enhancing memory in rats [2-3]. Of note is the fact that they did so utilizing independent molecular pathways.
